Physician profile
Matthew Bain
NPI 1851403018
$11,409.51
in general payments reported to CMS, 2019-2025
42 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $1,593 · 2021: $2,423 · 2022: $1,663 · 2023: $929 · 2024: $1,665 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,144 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,144.22 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,552.40 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,473.42 | 2019-2025 | |
| Lilly USA, LLC | $1,216.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,087.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $718.63 | 2019-2025 | Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $681.08 | 2019-2025 | Jardiance, Spiriva Respimat |
| Amgen INC. | $538.68 | 2019-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $441.84 | 2021-2025 | |
| Glaxosmithkline, LLC. | $414.94 | 2019-2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $337.16 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $317.83 | 2019-2024 | Spravato |
| Biohaven Pharmaceutical Holding Company Ltd. | $203.12 | 2022 | |
| Merck Sharp & Dohme LLC | $193.31 | 2019-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $177.96 | 2019-2024 | |
| Allergan, INC. | $165.89 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.